Connection
John Somberg to United States Food and Drug Administration
This is a "connection" page, showing publications John Somberg has written about United States Food and Drug Administration.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.520 |
|
|
|
-
Somberg JC. Drug shortages and ensuring the U.S. supply of needed pharmaceuticals. Am J Ther. 2012 Mar; 19(2):65.
Score: 0.548
-
Somberg JC. Has the food and drug administration changed the drug approval process? Am J Ther. 2011 May; 18(3):179.
Score: 0.517
-
Somberg J. FDA user fees and innovation. Am J Ther. 2008 Mar-Apr; 15(2):97.
Score: 0.415
-
Somberg J. Patent foramen ovale closure devices: thoughts from the circulatory device advisory panel. Am J Cardiol. 2007 Sep 01; 100(5):905-6.
Score: 0.395
-
Somberg J. The drug safety review process. Am J Ther. 2007 Mar-Apr; 14(2):119.
Score: 0.387
-
Somberg J. The report of the Institute of Medicine on drug safety. Am J Ther. 2007 Jan-Feb; 14(1):1-2.
Score: 0.383
-
Somberg JC. An opportunity to distance the FDA from Washington politics. Am J Ther. 2005 Nov-Dec; 12(6):475.
Score: 0.353
-
Somberg J. The provisional approval step. Am J Ther. 2005 Jan-Feb; 12(1):1-2.
Score: 0.333
-
Somberg JC. Restricting physician prescribing. Am J Ther. 2002 Sep-Oct; 9(5):369.
Score: 0.283
-
Somberg JC. Are we overregulated? Am J Ther. 2001 Jan-Feb; 8(1):1-2.
Score: 0.253
-
Somberg JC, McEwen P, Molnar J. Assessment of cardiovascular and noncardiovascular medical device recalls. Am J Cardiol. 2014 Jun 01; 113(11):1899-903.
Score: 0.158
-
Somberg J. The conflict of interest charade. Am J Ther. 2013 Nov-Dec; 20(6):591.
Score: 0.154
-
Somberg JC. Proposed accelerated FDA approvals for special medical use. Am J Ther. 2012 Nov; 19(6):393-4.
Score: 0.143
-
Somberg JC. Sharing regulatory review costs. J Clin Pharmacol. 1992 Oct; 32(10):867.
Score: 0.143
-
Somberg JC. Making America more competitive: a paradigm shift in drug and device development. Am J Ther. 2012 Sep; 19(5):315-6.
Score: 0.142
-
Somberg JC. The device development pinata. Am J Ther. 2011 Sep; 18(5):339.
Score: 0.132
-
Somberg JC. Inappropriate attack on device development. Am J Ther. 2011 Mar-Apr; 18(2):91.
Score: 0.128
-
Somberg JC. The Food and Drug Administration's paternalism. Am J Ther. 2010 Nov-Dec; 17(6):533-4.
Score: 0.125
-
Somberg JC, Preston RA, Ranade V, Molnar J. Developing a safe intravenous sotalol dosing regimen. Am J Ther. 2010 Jul-Aug; 17(4):365-72.
Score: 0.122
-
Somberg J. Device safety and effectiveness. Am J Ther. 2010 Jul-Aug; 17(4):357.
Score: 0.122
-
Somberg JC. The extrapolation of study results in the device approval process. Am J Cardiol. 2009 May 01; 103(9):1323-4.
Score: 0.111
-
Somberg JC. Securing the US pharmaceutical supply. Am J Ther. 2008 May-Jun; 15(3):197.
Score: 0.105
-
Somberg J. Mandatory post marketing studies. Am J Ther. 2007 Jul-Aug; 14(4):321.
Score: 0.099
-
Somberg J. Off-label promotion. Am J Ther. 2006 Sep-Oct; 13(5):387.
Score: 0.094
-
Somberg JC. Nesiritide: the wrong controversy. Am J Ther. 2005 Sep-Oct; 12(5):377-8.
Score: 0.087
-
Somberg J. Lessons learned from the COX-2 advisory hearings. Am J Ther. 2005 Mar-Apr; 12(2):105.
Score: 0.084
-
Somberg J. The politics of therapeutics. Am J Ther. 2004 Nov-Dec; 11(6):422.
Score: 0.082
-
Somberg J. Drug trial registries. Am J Ther. 2004 Sep-Oct; 11(5):327.
Score: 0.081
-
Somberg J. Should statins go OTC. Am J Ther. 2004 Jan-Feb; 11(1):1-2.
Score: 0.078
-
Somberg J. Therapeutics, drug pricing and innovation. Am J Ther. 2003 Nov-Dec; 10(6):381.
Score: 0.077
-
Somberg J. Clinical trials registries. Am J Ther. 2003 Sep-Oct; 10(5):309-10.
Score: 0.076
-
Somberg JC. Old drugs, new bottles, therapeutic advantage? Am J Ther. 2002 Jul-Aug; 9(4):273-4.
Score: 0.070
-
Somberg JC. Proposed product labeling changes: does it really matter? Am J Ther. 2001 May-Jun; 8(3):145-6.
Score: 0.065
-
Somberg JC. Adverse drug reaction reporting. Am J Ther. 2000 Aug; 7(4):227-8.
Score: 0.061
-
Somberg JC. Medical judgment and therapeutics. Am J Ther. 1999 Nov; 6(6):291-2.
Score: 0.058
-
Somberg JC, Borer JS. Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process. Am J Ther. 1999 May; 6(3):175-8.
Score: 0.056